Table 2.

ROC analysis

Model 1: Stage 1 Versus Non-DM				Model 2: Stage 2 Versus Stage 1				Model 3: Stage 3–4 Versus Stage 2
Factor	Auroc	95% CI	P Value	Factor	Auroc	95% CI	P Value	Factor	Auroc	95% CI	P Value
μAlb	0.932	0.889–0.975	<0.001	μAlb	0.808	0.733–0.883	<0.001	μAlb	0.987	0.962–1.000	<0.001
tetranor-PGEM	0.791	0.717–0.866	<0.001	tetranor-PGEM	0.657	0.561–0.753	0.004	Lyso-PAF	0.849	0.761–0.938	<0.001
13,14-dihydro-15-keto-PGE2	0.733	0.652–0.814	<0.001	9,10-DiHOME	0.627	0.530–0.724	0.019	Maresin-1	0.823	0.727–0.919	<0.001
PGE2	0.721	0.623–0.819	<0.001	Lyso-PAF	0.602	0.504–0.701	0.059	5-iPF2α-VI	0.780	0.665–0.895	<0.001
13,14-dihydro-15-keto-tetranor-PGE2	0.714	0.615–0.813	<0.001					LTB4-EA	0.716	0.611–0.821	0.002
PGD2	0.651	0.537–0.766	0.008					2,3-dinor-TXB2	0.713	0.607–0.819	0.002
9,10-DiHOME	0.629	0.524–0.733	0.025					11-dehydro-TXB2	0.642	0.511–0.773	0.038
8-iso-PGE2	0.622	0.525–0.719	<0.05